Jazz Pharmaceuticals plc JAZZ
Set alert
At close · Nov 2
After hours · Nov 2, 6:16 PM ET
- YTD
- +26.14%
- 1 year
- +55.80%
- Open
- 215.84
- Prev close
- 215.98
- Mkt cap
- 13.92B
- Vol
- 1.04M
- Avg vol
- 899.55K
- EPS
- 14.59
- P/E
- 14.70
- Div yield
- 0.00%
More statistics
- Low
- 213.81
- High
- 218.36
- Forward P/E
- 8.51
- Beta
- 0.37
- Short ratio
- 6.86
- Inst. own
- 103.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 231.96
- 200-d avg
- 216.63
- 1y target
- 295.36
15m chart
Built from the cached five-day intraday bars.
Events in this range
- Oct 28, 2026Rating: JP Morgan · Overweight → Overweight
- Nov 2, 2026Earnings: —; estimate -4.05; surprise —%
Signals (33)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 7 hours ago |
| SMA: Bearish | Nov 2, 3:40 PM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 7 hours ago |
| MACD: Buy Signal | Nov 2, 3:10 PM | 8 hours ago |
| SMA: Bullish | Nov 2, 1:55 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 12 hours ago |
| RSI: Overbought | Oct 30, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:25 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:55 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:10 PM | 3 days ago |
| RSI: Overbought | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
Newest 20 of 33.
Key statistics
- Market cap
- 13.92B
- Enterprise value
- 16.23B
- Trailing P/E
- 14.70
- Forward P/E
- 8.51
- PEG ratio
- 0.96
- Price / sales
- 3.03
- Price / book
- 2.89
- EPS (TTM)
- 14.59
- Beta
- 0.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.45%
- Revenue (TTM)
- 4.60B
- Revenue growth
- 15.50%
- Free cash flow
- 1.43B
- Total cash
- 2.20B
- Total debt
- 4.41B
- Return on equity
- 22.11%
- Shares outstanding
- 64.91M
- Short % of float
- 9.30%
- 50-day average
- 231.96
- 200-day average
- 216.63
Analyst view
Consensus: strong buy
- Target (low)
- 225.00
- Target (mean)
- 295.36
- Target (high)
- 337.00
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -2.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -4.05 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 6.18 | 5.71 | -0.47 | -7.61% |
| May 5, 2026 | Mar 31, 2026 | 4.64 | 6.34 | +1.70 | +36.64% |
| Feb 24, 2026 | Dec 31, 2025 | 6.52 | 6.64 | +0.12 | +1.84% |
| Nov 5, 2025 | Sep 30, 2025 | 5.95 | 8.13 | +2.18 | +36.64% |
| Aug 5, 2025 | Jun 30, 2025 | -6.12 | -8.25 | -2.13 | -34.80% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 11, 2026 | UBS | main | Buy | Buy |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- jazzpharma.com
News
- Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
- Jazz Pharmaceuticals Q3 Earnings Call Highlights
- Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
- Jazz Pharmaceuticals Q3 2026 Earnings Call Transcript
- Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.600B-$4.750B to $4.775B-$4.850B vs $4.719B Est
- Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B Estimate
- Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
- Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
- Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
Your note
Sign in to keep a note on JAZZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COZADD BRUCE C | Director | Sale | Sep 30, 2026 | 345,875 |
| ENRIGHT PATRICK G. | Director | Stock Award(Grant) | Aug 4, 2026 | 22,984 |
| GALA RENEE D | Chief Executive Officer | Sale | Oct 5, 2026 | 141,394 |
| HENDERSON MARY ELIZABETH | Officer | Sale | Feb 25, 2026 | 28,728 |
| IANNONE ROBERT | Officer | Conversion of Exercise of derivative security | Aug 26, 2026 | 65,686 |
| JOHNSON PHILIP L | Chief Financial Officer | Stock Award(Grant) | Feb 25, 2026 | 62,223 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.19% | 5,968,603 | 1.28B | Jun 29, 2026 |
| FMR, LLC | 7.10% | 4,609,326 | 988.42M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.68% | 3,036,213 | 651.09M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 2,729,650 | 585.35M | Jun 29, 2026 |
| Capital World Investors | 4.16% | 2,697,610 | 578.48M | Jun 29, 2026 |
| LSV Asset Management | 3.50% | 2,275,145 | 487.88M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 2,312,286 | 495.85M | Sep 29, 2026 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 2.93% | 1,900,000 | 407.44M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 1,892,522 | 405.83M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.41% | 1,561,563 | 334.86M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.11% | 1,366,767 | 293.09M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.33% | 865,937 | 185.69M | Jun 29, 2026 |